Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

RAB0537

Sigma-Aldrich

Human FABP2 / Fatty Acid-Binding Protein, Intestinal ELISA Kit

for serum, plasma, cell culture supernatants and urine

Synonym(s):

FABP2 ELISA Kit, Intestinal FABP2 Detection

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41116158
NACRES:
NA.32

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable

input

sample type plasma
sample type serum
sample type urine
sample type cell culture supernatant(s)

assay range

inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 25 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... FABP2(2169)

General description

The antibody pair provided in this kit detects Intestinal, Human Fatty Acid-Binding Protein in serum, plasma, cell culture supernatants, and urine.

Fatty acid-binding protein (FABP2) is an intracellular protein, encoded by the gene mapped to human chromosome 4q28–q31.It is expressed in intestinal enterocytes. FABP2 codes for intestinal FABP (I-FABP).

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Biochem/physiol Actions

Fatty acid-binding protein (FABP2) plays a vital role in the absorption and intracellular migration of dietary long-chain fatty acids. It also helps in the metabolism of fatty acids. FABP2 acts as a candidate gene for diabetes and insulin resistance. It is also implicated in lipid metabolism and adipogenesis.

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Kit Components Also Available Separately

Product No.
Description
SDS
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS
  • RABSTOP3ELISA Stop Solution (Item I)SDS
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDS
  • RABELADCELISA 1X Assay/Sample Diluent Buffer C (Item L)SDS
  • RABWASH420X Wash Buffer (Item B)SDS

Pictograms

Corrosion
GHS05

Signal Word

Warning

Hazard Statements

H290

Precautionary Statements

P234 - P390

Hazard Classifications

Met. Corr. 1

Storage Class Code

8A - Combustible corrosive hazardous materials

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marina Saresella et al.
Frontiers in immunology, 11, 1390-1390 (2020-08-01)
Background: Butyric acid (BA) is a short-chain fatty acid (SCFA) with anti-inflammatory properties, which promotes intestinal barrier function. Medium-chain fatty acids (MCFA), including caproic acid (CA), promote TH1 and TH17 differentiation, thus supporting inflammation. Aim: Since most SCFAs are absorbed
Brynjulf Mortensen et al.
Gastroenterology, 157(3), 637-646 (2019-05-17)
Enteropathy and small-intestinal ulcers are common adverse effects of nonsteroidal anti-inflammatory drugs such as acetylsalicylic acid (ASA). Safe, cytoprotective strategies are needed to reduce this risk. Specific bifidobacteria might have cytoprotective activities, but little is known about these effects in
Nicole U Stoffel et al.
The Lancet. Haematology, 4(11), e524-e533 (2017-10-17)
Current guidelines to treat iron deficiency recommend daily provision of ferrous iron divided through the day to increase absorption. However, daily dosing and split dosing might increase serum hepcidin and decrease iron absorption from subsequent doses. Our study aim was
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.
Furuhashi M and Gokhan S H
Nature Reviews. Drug Discovery, 7(6), 489-489 (2008)
Daniela Paganini et al.
Gut, 66(11), 1956-1967 (2017-08-05)
Iron-containing micronutrient powders (MNPs) reduce anaemia in African infants, but the current high iron dose (12.5 mg/day) may decrease gut In a 4-month, controlled, double-blind trial, we randomised Kenyan infants aged 6.5-9.5 months (n=155) to receive daily (1) a MNP without
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service